Tums touts a ‘fresh’ take

Tums has proven to be the Houdini of digestive tablets — surviving all digestive switch products from H2 blockers through proton-pump inhibitors, and still growing. For the 12 weeks ended Jan. 12, sales of Tums were up more than 3%, and it still was among the top three antacids.


GSK’s latest Tums innovation comes in the form of Tums Freshers, a new tablet-size version of Tums that is 40% smaller than regular Tums and includes a cooling flavor for breath freshening because 94% of heartburn sufferers also report having bad breath when they experience heartburn, according to a recent GSK survey.

The article above is part of the DSN Category Review Series. For the complete Antacids Sell-Through Report, including extensive charts, data and more analysis, click here.